AVXL had good results for the Alzheimer's IIb/3 clinical trial, statistically significant improvements. Their drug does not target dissolving amyloid plaques, it's trying to stop the disease further upstream before the plaques form.

This stock had been beaten down. Up 23% now, and on a huge down day for the broader market. I'm really a little surprised it's not up more.

So, big moves up can happen, even in a market meltdown, for a novel mechanism of action. I'm posting this because of all the other posts about Alz drugs recently.

https://finance.yahoo.com/news/anavex-blarcam...00308.html